Intervention

clozapine

ClinicalTrials.gov intervention label

Clinical trials9

Recruiting2

Common conditions12

Lead sponsors shown9

Clinical trials

9 shown

Biomarkers to Enhance Early Schizophrenia TreatmentNCT06969755 · 2024-09-04

CLOZAPINE Response in Biotype-1NCT04580134 · 2022-03-01

A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's DiseaseNCT07085195 · 2025-08-01

NOT_YET_RECRUITING

The Optimal Treatment for Treatment-resistant SchizophreniaNCT02926976 · 2016-11-01

F-18 Altanserin PET Study of Patients Receiving ClozapineNCT01398189 · 2011-07-01

First Episode Schizophrenia and Cannabis-Related Disorder StudyNCT00573287 · 2006-06-01

CATIE- Schizophrenia TrialNCT00014001 · 2000-12-01

Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's DiseaseNCT00004826 · 1993-10-01

Clozapine IM and Aggression in Schizophrenic PatientsNCT00189995

Common conditions

Schizophrenia6 Schizoaffective Disorder2 Bipolar 1 Disorder1 Cannabis-Related Disorder1 Clozapine1 Gene Therapy1 Parkinson Disease1 Parkinson Disease (PD)1 Psychotic Disorders1 Safety and Efficacy1 Schizophenia Disorder1 Substance-Related Disorders1

Leading sponsors

Beersheva Mental Health Center1 Dartmouth-Hitchcock Medical Center1 Memorial Hospital of Rhode Island1 National Institute of Mental Health (NIMH)1 Northwell Health1 Ruijin Hospital1 Seoul National University Bundang Hospital1 Shanghai Mental Health Center1 University of Texas Southwestern Medical Center1

Trial status mix

COMPLETED3

RECRUITING2

UNKNOWN2

NOT_YET_RECRUITING1

WITHDRAWN1

Phase mix

NA4

PHASE43

EARLY_PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.